



RECEIVED

JAN 10 2001

TECH CENTER 1500-2900

FORM PTO-1449	SERIAL NO./ TRADEMARK	CASE NO.: 49321-16
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE 2/16/00	GROUP ART UNIT 1642
(use several sheets if necessary)	APPLICANT(S): Clinton & Doherty	

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
AZH	A1	5,720,937	02-24-1998	Hudziak et al.	424/9.34	
AZH	A2	5,401,638	03-28-1995	Carney et al.	435/7.23	
AZH	A3	5,604,107	02-18-1997	Carney et al.	435/7.23	
AZI+	A4	5,783,186	07-21-1998	Arakawa et al.	424/143.1	
AZH	A5	6,015,567	01-18-2000	Hudziak et al.	424/277.1	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
AZI+	A6	EP 0412116	04-18-1989	Applied Biotechnology, Inc.	C12Q 1/68	
AZH	A7	EP 0494135	09-29-1989	Oncogene Science, Inc.	G01N 33/574	

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
AZH	A8	“Circulatory HER2 extracellular domain (CCD) levels in Multiple Tumor Xenograft Models of HER-overexpressing Breast Cancer,” Park, J.W., G. Colbern, A. Duijens, J. Baselga, D. Papahadjopoulos, C.C. Benz, UCSF, California; Geraldine Brush Cancer Research Institute, CPMC, SF, CA; Genentech, Inc. So. S.F., CA; Memorial Sloan-Kettering Cancer Center, NY, NY.
AZI+	A9	Christianson, Tracy A. et al., “NH ₂ -terminally truncated HER-2/neu Protein: Relationship with Shedding of the Extracellular Domain and with Prognostic Factors in Breast Cancer,” <i>Cancer Research</i> 58, 5123-5129, Nov. 15, 1998.

June L. Hansen 1/25/03